Načítá se...
Androgen Receptor Variant–Driven Prostate Cancer II: Advances in Laboratory Investigations
BACKGROUND: The androgen receptor (AR) is a key prostate cancer drug target. Suppression of AR signaling mediated by the full-length AR (AR-FL) is the therapeutic goal of all existing AR-directed therapies. AR-targeting agents impart therapeutic benefit, but lead to AR aberrations that underlie dise...
Uloženo v:
| Vydáno v: | Prostate Cancer Prostatic Dis |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7725416/ https://ncbi.nlm.nih.gov/pubmed/32139878 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-020-0217-3 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|